This policy brief provides antiretroviral therapy programme managers, implementing partners, procurement and supply chain managers, and other relevant stakeholders with key points to consider before and during the introduction of the new dosage form of ritonavir-boosted lopinavir (LPV/r) oral pellets.

While there are many separate indicators related to sexual and reproductive health (SRH) and HIV, a key challenge has been the lack of internationally agreed indicators to measure progress in linking SRH and HIV. This SRH and HIV Linkages Compendium contains a focused set of indicators and related assessment tools that have relevance to tracking the links between SRH and HIV programmes at national and sub-national levels.

Each indicator includes an overview, a brief description of its relevance to SRH and HIV linkages, and a hyperlink to a detailed definition.  All the indicators in this compendium have passed through a rigorous evaluation based on the indicator standards of the UNAIDS Monitoring and Evaluation Reference Group.

In response to a longstanding demand for a heat-stable and easy to administer formulation of ritonavir boosted lopinavir (LPV/r) for infants and young children, a new formulation in pellet form is now available.

This fact sheet provides simplified information to facilitate proper dosing and administration of lopinavir and ritonavir 40mg/10mg oral pellets.

This compendium of case studies showcases innovative approaches to integrated HIV-SRH service delivery for improving MNCH outcomes, and strengthening health and community systems. It is hoped that the 11 case studies included in this publication will help to inform future programming by providing examples of promising practices related to integration in sub-Saharan Africa in order to extrapolate the common elements of, and barriers to, effective integrated service delivery.

This publication is an update of the 2005 guidelines for measuring national HIV prevalence in population-based surveys of the UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance.

The purpose of the revised guidelines is to assist programme officers in monitoring the HIV epidemic and the impact of the country’s AIDS response by designing and implementing population-based surveys that include HIV infection, sexually transmitted infections, and other bloodborne biomarkers.

This document provides guidance on monitoring and evaluating the implementation of the comprehensive package of interventions to address HIV among key populations: men who have sex with men, people in prisons and other closed settings, people who inject drugs, sex workers and transgender people.

This document provides countries with:

• a set of harmonized indicators to examine the implementation of the package of interventions to address HIV among key populations; and
• guidance on setting targets for these indicators.

This document updates the 2013 consolidated guidelines on the use of antiretroviral drugs following an extensive review of evidence and consultations in mid-2015, shared at the end of 2015, and now published in full in 2016. It is being published in a changing global context for HIV and for health more broadly.

The purpose of this framework is to provide operational guidance on monitoring and evaluation of pregnant and breastfeeding women receiving ART for life and their HEIs. This document is organized around a series of recommendations for the operationalization of monitoring, both routine (Section 1) and enhanced (Section 2), and the evaluation (Section 3) of programmes implementing lifelong ART for pregnant and breastfeeding women and their infants.